Eshwar Meduri

Eshwar Meduri

Auto-generated profile, based on publicly available information

Eshwar Meduri

Wellcome - MRC Cambridge Stem Cell Institute, Cambridge, UK

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2022 in iScience
Verified
Journal Article
Open access
EMEshwar Meduri
Eshwar Meduri
CBCharles Breeze
Charles Breeze
LMLudovica Marando
Ludovica Marando
SRSimon E. Richardson
Simon E. Richardson
BHBrian J.P. Huntly
Brian J.P. Huntly
Several studies have documented aberrant RNA editing patterns across multiple tumors across large patient cohorts from The Cancer Genome Atlas (TCGA). However, studies on understanding the role of RNA editing in acute myeloid leukemia (AML) have been limited to smaller sample sizes. Using high throughput transcriptomic data from the TCGA, we demonstrated higher levels of editing as a predictor of poor outcome within the AML patient samples. Moreover, differential editing patterns were observed across individual AML genotypes. We also could demonstrate a negative association between the degree of editing and mRNA abundance for some transcripts, identifying the potential regulatory potential of RNA-editing in altering gene expression in AML. Further edQTL analysis suggests potential cis-regulatory mechanisms in RNA editing variation. Our work suggests a functional and regulatory role of RNA editing in the pathogenesis of AML and we extended our analysis to gain insight into the factors influencing altered levels of editing.